Abstract
Intraprostatic injection of onabotulinumtoxin A (onabotA) has been explored recently as a new treatment for LUTS due to BPE/BPH in patients who are refractory to medical treatment with poor surgical conditions. In this study we evaluate the distribution of the toxin injected in the gland through MRI imaging and describe the localization of synaptic vesicle protein 2 (SV2), the onabotA high-affinity receptor, in the human prostate.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have